Royal Philips

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment businesses; Connected Care businesses; Personal Health businesses; and Other. The Diagnosis and Treatment businesses segment consists systems, smart devices, software and services, powered by AI-enabled informatics-that support precision diagnoses and minimally invasive procedures in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care businesses segment consists Hospital Patient Monitoring, Emergency Care, Sleep & Respiratory Care and Connected Care Informatics. The Personal Health businesses segment consists of Oral Healthcare, Personal Care,Mother and Child Care. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

June 30, 2022 Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment   Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix , Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, to incorporate the results of Biodesix's Nodify Lung ® blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data – along with the radiologic and patient history data currently used to determine treatment decisions – can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases, via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator. Philips Lung Cancer Orchestrator solution is designed to enable health systems to operationalize lung cancer screening and lung nodule management programs at scale. Lung cancer remains the leading cause of cancer deaths worldwide [1], with current 5-year survival rates after diagnosis typically less than 20% [2]. If detected and treated early, however, research shows 10-year survival rates could increase to more than 90% [3]. Thanks to the adoption of low-dose CT (computer tomography) screening and better management of incidental lung nodule findings, early-stage diagnosis and treatment is now possible, but has resulted in rapidly increasing caseloads. For example, recent changes in U.S. guidelines have nearly doubled the number of people now eligible for lung cancer screening [4]. “By incorporating Biodesix's Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view,” said Louis Culot, General Manager Oncology Informatics and Genomics at Philips. “We expect the inclusion of Biodesix's ground-breaking technology in Philips Lung Cancer Orchestrator to help drive more confident decisions for the care team, and ultimately benefit patients.” As a next-step after radiologic lung nodule assessment, minimally-invasive biopsy procedures such as endobronchial biopsy (accessing a nodule via the patient's airways), are already helping early-stage diagnosis. With 62% of biopsies conducted on benign nodules [5], by detecting the presence of blood-based biomarkers combined with clinical and radiomic factors, Biodesix's Nodify Lung blood-based proteomic tests help clinicians to reclassify the risk of malignancy to better target resources to those who need them. If a nodule is malignant, the delay in surgical care for cancer patients by four weeks increases the mortality by 6-8% [6]. “We are delighted that our tests are being incorporated into Philips' vision for end-to-end cancer care management using a multi-diagnostic approach,” said Scott Hutton, Chief Executive Officer at Biodesix. “By integrating our Nodify® tests in Philips Lung Cancer Orchestrator we hope to make these tests more accessible to physicians and patients and more easily utilized by care teams with the ultimate goal of improving patient care and outcomes.” Philips Lung Cancer Orchestrator is an integrated patient management system for CT lung cancer screening programs and incidental lung nodule findings that keeps track of patients, appointments, diagnostic images, test results, and clinical decisions for every step of a lung cancer patient's screening and treatment journey. Fitting seamlessly into conventional screening and diagnostic workflows, it coordinates the end-to-end patient journey to create a fully traceable, fully documented timeline of scheduled actions, and aggregates data on tumor staging, radiology, pathology, and biomarker analyses for informed decision-making. The ability to order and receive the results expedites Biodesix's proteomic testing directly to and from the Lung Cancer Orchestrator at the same time it adds new insights on nodule risk of malignancy to further support the decision-making process. Lung Cancer Orchestrator is part of Philips' expanding portfolio of integrated cancer care solutions that seamlessly connect data, technology, operations, and clinical workflows to enable pivotal decision-making. Visit Philips Oncology to learn how Philips combines smart diagnostic and imaging technologies with connected workflows that integrate patient data from disparate systems, to provide solutions that put expert information at clinicians' fingertips to help expand the quality and reach of personalized cancer care. [1] International Agency for Research on Cancer, World Health Organization. Press Release N° 263. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. 12 September 2018[2] https://www.medicinenet.com/what_is_the_most_survivable_cancer/article.htm [3] International Early Lung Cancer Action Program Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med. 2006;355:1763- 1771 DOI: 10.1056/NEJMoa060476.[4] Lane E, et al. Nearly twice as many people are now eligible for lung cancer screenings—here is what you need to know. Advisory Board publication. 2021.Washington, DC. https://www.advisory.com/sponsored/lung-cancer [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665735/ [6] Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 2020;371:m4087 http://dx.doi.org/10.1136/bmj.m4087 For further information, please contact: Kathy O'ReillyPhilips Global Press OfficeTel.: +1 978-221-8919E-mail: kathy.oreilly@philips.com Twitter: @kathyoreilly About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter . About Biodesix Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.

Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

Philips provides update on Philips Respironics' PE-PUR sound abatement foam test and research program

Team OneBlade highlights Philips Norelco OneBlade, the innovative tool that can trim, edge and shave any length of hair so guys look and feel their best STAMFORD, Conn. , June 21, 2022 /PRNewswire/ -- Philips Norelco knows that draft night is among the biggest moments of any top professional basketball prospect's athletic career.

Philips drafts top prospects Paolo Banchero, Jaden Hardy, Chet Holmgren, and Jalen Williams to "Team OneBlade," an exclusive roster of players who look and feel their best on and off the basketball court

Philips awarded top honor by Red Dot jury with Design Team of the Year award

Philips to repurchase up to 3.2 million shares to cover long-term incentive and employee stock purchase plans

Philips announces positive three-year clinical research results from its Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial

In this article, we'll take a look at perhaps one of the most well-known conglomerates on Earth, Philips, with the original name Koninklijke Philips N.V. The company has a 100-year history, and has had some issues in the past few decades.

Philips: Upside From A Massive Conglomerate

Philips' Future Health Index 2022 report shows healthcare leaders are rebooting priorities as they emerge from the pandemic

Philips announces exchange ratio for 2021 dividend

Willem Appelo to succeed Sophie Bechu as Philips' Chief Operations Officer

Philips Foundation publishes its 2021 Annual Report

Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.

Philips' (PHG) Launches a Range of New Products at EuroPCR 2022

Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022

New release of Philips EchoNavigator helps interventional teams treat structural heart disease with greater ease and efficiency

Philips Annual General Meeting of Shareholders approves dividend and other proposals made to shareholders

Philips shareholders voted against the company's executive compensation plan at the annual shareholders' meeting on Tuesday, ANP reported, in a protest over the company's recent poor results and product recalls.

Philips shareholders vote against executive compensation plan

Philips receives FDA 510(k) clearance for latest breakthrough high-performance MR 7700 system

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)) OR ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE US VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS NOTICE.

Koninklijke Philips N.V.: Tender Offers Results Notice

Koninklijke Philips N.V.: Announcement of the indicative Series Acceptance Amounts

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN, ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL

Koninklijke Philips N.V. Announces Tender Results of Any and All Tender Offer for Certain Outstanding USD-Denominated Notes

Koninklijke Philips N.V. Announces Pricing Terms of Any and All Tender Offer for Certain Outstanding USD-Denominated Notes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has again been recognized on Forbes's America's Best Employers for Diversity 2022 list. Philips' inclusion in this important ranking is a testament to the company's commitment to fostering a diverse and inclusive culture where employees feel valued, safe and supported to be their best. Philips ranked 195 on the 2022 list and is among the top five in the ‘Health

Philips Named to Forbes Best Employers for Diversity 2022 List

Philips at ESOC 2022: showcasing integrated solutions across the stroke care pathway

Philips successfully prices offering of Notes for EUR 2 billion

Philips and Prisma Health sign multi-year, long-term strategic partnership to innovate healthcare across the enterprise and unlock the power of patient data

News for Royal Philips Stock (PHG)